These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 17354267)

  • 21. Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials.
    De Berardis D; Marini S; Serroni N; Iasevoli F; Tomasetti C; de Bartolomeis A; Mazza M; Tempesta D; Valchera A; Fornaro M; Pompili M; Sepede G; Vellante F; Orsolini L; Martinotti G; Di Giannantonio M
    Curr Drug Targets; 2015; 16(10):1094-106. PubMed ID: 25944011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment.
    Neylan TC; Lenoci M; Samuelson KW; Metzler TJ; Henn-Haase C; Hierholzer RW; Lindley SE; Otte C; Schoenfeld FB; Yesavage JA; Marmar CR
    Am J Psychiatry; 2006 Dec; 163(12):2186-8. PubMed ID: 17151174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prazosin in PTSD.
    Brkanac Z; Pastor JF; Storck M
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):384-5. PubMed ID: 12649625
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging treatments for PTSD.
    Cukor J; Spitalnick J; Difede J; Rizzo A; Rothbaum BO
    Clin Psychol Rev; 2009 Dec; 29(8):715-26. PubMed ID: 19800725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healing trauma: finding treatments that work.
    Paquette M
    Perspect Psychiatr Care; 2007 Jul; 43(3):113. PubMed ID: 17576303
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapeutic use of agents acting on alpha and beta receptors].
    Soballa G
    Fortschr Med; 1974 Apr; 92(11):461-6. PubMed ID: 4150787
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroethics and psychiatry.
    Levy N; Clarke S
    Curr Opin Psychiatry; 2008 Nov; 21(6):568-71. PubMed ID: 18852564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-traumatic stress disorder in somatic disease: lessons from critically ill patients.
    Schelling G
    Prog Brain Res; 2008; 167():229-37. PubMed ID: 18037018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prazosin for treatment of nightmares related to posttraumatic stress disorder.
    Taylor HR; Freeman MK; Cates ME
    Am J Health Syst Pharm; 2008 Apr; 65(8):716-22. PubMed ID: 18387899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the role of noradrenergic system in PTSD and related sleep disturbances. The use of terazosin in PTSD related nightmares: a case report.
    Salviati M; Pallagrosi M; Valeriani G; Carlone C; Todini L; Biondi M
    Clin Ter; 2013; 164(2):133-7. PubMed ID: 23698207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-traumatic Stress Disorder in children and adolescents: from Sigmund Freud's "trauma" to psychopathology and the (Dys)metabolic syndrome.
    Pervanidou P; Chrousos GP
    Horm Metab Res; 2007 Jun; 39(6):413-9. PubMed ID: 17578757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder.
    Southwick SM; Bremner JD; Rasmusson A; Morgan CA; Arnsten A; Charney DS
    Biol Psychiatry; 1999 Nov; 46(9):1192-204. PubMed ID: 10560025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and management of posttraumatic stress disorder in returning veterans.
    Reeves RR
    J Am Osteopath Assoc; 2007 May; 107(5):181-9. PubMed ID: 17596586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update.
    Bajor LA; Balsara C; Osser DN
    Psychiatry Res; 2022 Nov; 317():114840. PubMed ID: 36162349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adrenergic agonists and antagonists in the treatment of hypovolemic shock.
    Williamson M
    J Am Med Womens Assoc; 1969 Dec; 24(12):951-6 passim. PubMed ID: 4391032
    [No Abstract]   [Full Text] [Related]  

  • 36. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder.
    O'Donnell T; Hegadoren KM; Coupland NC
    Neuropsychobiology; 2004; 50(4):273-83. PubMed ID: 15539856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of clonidine in post-traumatic stress disorder.
    Porter DM; Bell CC
    J Natl Med Assoc; 1999 Aug; 91(8):475-7. PubMed ID: 12656438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revisiting propranolol and PTSD: Memory erasure or extinction enhancement?
    Giustino TF; Fitzgerald PJ; Maren S
    Neurobiol Learn Mem; 2016 Apr; 130():26-33. PubMed ID: 26808441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.
    Pae CU; Lim HK; Ajwani N; Lee C; Patkar AA
    Expert Rev Neurother; 2007 Jun; 7(6):603-15. PubMed ID: 17563244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Central and peripheral alpha-agonist and antagonist drugs in pharmacology and therapy].
    Basile V; Marino A
    Clin Ter; 1989 Dec; 131(6):363-71. PubMed ID: 2576645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.